Sylvester Comprehensive Cancer Center’s Dr. Jashodeep Datta Wins Stanley J. Glaser Award for Pancreatic Cancer Immunotherapy
Summary
- Dr. Jashodeep Datta received the Stanley J. Glaser Award for his rising impact in pancreatic cancer immunotherapy research.
- His work focuses on decoding immune‑driven treatment resistance to develop more precise therapies for pancreatic cancer and to deliver these therapies earlier in the treatment course for patients eligible for surgery.
- A key strength of the proposal is its emphasis on neoadjuvant immunotherapy, addressing a critical window to improve surgical outcomes and long‑term disease control in pancreatic cancer.
At Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine, innovation begins with a question, the kind that sits just beyond what science currently understands. For Jashodeep Datta, M.D., the DiMare Family Endowed Chair in Immunotherapy and associate professor in the Division of Surgical Oncology at the Miller School, those questions have driven a career defined by curiosity, rigor and a deep commitment to improving outcomes for patients with some of the most lethal cancers.
Today, that work has earned him the Stanley J. Glaser Foundation Research Award, a prestigious recognition given to rising research leaders at the University of Miami whose work shows exceptional promise for transforming care.
A Research Program Built on Bold Ideas
Dr. Datta leads a translational research lab at Sylvester, where he examines how pancreatic tumors manipulate their surroundings to evade the immune system. His research focuses on the intersection of immune dysfunction, therapeutic resistance and tumor biology and cellular interactions in the tumor microenvironment, with a special emphasis on myeloid immunobiology.
“This award energizes our team’s commitment to asking brave questions about what makes pancreatic cancers so hard to treat,” said Dr. Datta. “Every insight we uncover moves us closer to new treatments that engage the immune system and are smarter, more precise and more humane for our patients.”
As co-leader of Sylvester’s Gastrointestinal Site Disease Group and assistant director of transdisciplinary research at Sylvester, Dr. Datta has also helped expand the portfolio of investigator‑initiated clinical trials in GI cancers and accelerate the development of new precision treatments. His work has already been recognized nationally, including the Joan L. and Julius H. Jacobson II Promising Investigator Award from the American College of Surgeons and the Young Physician-Scientist Award from the American Society for Clinical Investigation.
Seed Funding from the Glaser Award
Each year, the Stanley J. Glaser Foundation Research Awards provide seed funding for emerging research leaders whose ideas have the potential to reshape medicine. By placing Dr. Datta among this distinguished cohort, the Glaser Foundation underscores the transformative promise of his work.
Pancreatic cancer remains one of the deadliest tumor types, with survival rates that have barely shifted in decades. Dr. Datta’s research explores foundational questions:
• Why do some immune cells morph into tumor‑promoting forces?
• Why do certain treatments fail?
• What molecular levers can be pulled to bring the immune system back into the fight?
His team has contributed essential discoveries, including identifying signaling circuits that sustain immune suppression and pinpointing therapeutic vulnerabilities. His vision is to develop combination therapies uniquely tailored to each tumor’s biology, moving toward true precision immunotherapy for this cancer.
Dr. Datta plans to use the Glaser Award to advance a new treatment approach that blocks the interleukin-1 (IL-1) inflammatory pathway. This pathway is one of the signals that pancreatic cancers use to create a protective environment that weakens the body’s immune response and fuels resistance to therapy. His team will test whether disrupting this pathway can make chemotherapy and immunotherapy work better, while also identifying tissue- and blood-based biomarkers that help predict which patients are most likely to benefit from this therapy. These studies are designed to fuel a “bench-to-bedside” framework to launch an investigator-initiated clinical trial at Sylvester that evaluates this novel combination treatment—IL-1 blocker plus chemoimmunotherapy—for patients with operable pancreatic cancer.
A Rising Scientific Force at Sylvester
Throughout his career, Dr. Datta has emphasized that major scientific breakthroughs are collective achievements. He credits his teams and the institutional infrastructure championed by Sylvester leadership—for empowering his lab to pursue high‑risk, high‑reward science.
His appointment as the DiMare Family Endowed Chair in Immunotherapy further reflects the confidence placed in his leadership and pioneering scholarship.
With the Glaser Award, Dr. Datta joins a select group of investigators positioned to redefine their fields. For Sylvester and the Miller School, his recognition represents a larger narrative, one of exceptional talent rising within a rapidly growing biomedical research enterprise.
Dr. Datta’s work exemplifies Sylvester’s mission: translating discovery into meaningful, life-changing therapies for patients.
As his lab continues to investigate how to outsmart pancreatic tumors at the molecular and immunologic levels, Dr. Datta stands at the forefront of a new era of cancer immunotherapy driven by precision, possibility and the pursuit of cures.
“My patients are my North Star,” Dr. Datta said. “Every breakthrough begins with this in mind, and hope that the next discovery will give patients more time, more options and more life. This award strengthens our resolve to keep pushing forward for a future in which all patients with pancreatic cancer can thrive.”
Tags: cancer research, chemotherapy, immune system, immunotherapy, Newsroom, pancreatic cancer, Stanley J. Glaser Foundation, Sylvester Comprehensive Cancer Center